A Double-blind, Placebo-controlled, Phase-II Clinical Trial to Evaluate Oral Simvastatin As a Treatment for Vitiligo

Overview

Journal J Am Acad Dermatol

Specialty Dermatology

Date 2016 Dec 18

PMID 27986135

Citations 11

Authors

Stefan G Vanderweil

Shinya Amano

Wei-Che Ko

Jillian M Richmond

Michelle Kelley

Maryanne Makredes Senna

Andrea Pearson

Sandhya Chowdary

Celia Hartigan

Bruce Barton

John E Harris

Affiliations

Soon will be listed here.

Citing Articles

Vitiligo: From Pathogenesis to Treatment.

Speeckaert R, Caelenberg E, Belpaire A, Speeckaert M, van Geel N J Clin Med. 2024; 13(17).

PMID: 39274437 PMC: 11396398. DOI: 10.3390/jcm13175225.

Topical application of simvastatin acid sodium salt and atorvastatin calcium salt in vitiligo patients. Results of the randomized, double-blind EVRAAS pilot study.

Niezgoda A, Winnicki A, Krysinski J, Niezgoda P, Nowowiejska L, Czajkowski R Sci Rep. 2024; 14(1):14612.

PMID: 38918590 PMC: 11199485. DOI: 10.1038/s41598-024-65722-w.

Etiopathogenesis and Emerging Methods for Treatment of Vitiligo.

Iwanowski T, Kolkowski K, Nowicki R, Sokolowska-Wojdylo M Int J Mol Sci. 2023; 24(11).

PMID: 37298700 PMC: 10253679. DOI: 10.3390/ijms24119749.

Implementation of the vitiligo area scoring index in clinical studies of patients with vitiligo: a scoping review.

Ceresnie M, Warbasse E, Gonzalez S, Pourang A, Hamzavi I Arch Dermatol Res. 2023; 315(8):2233-2259.

PMID: 37029284 DOI: 10.1007/s00403-023-02608-3.

Research Progress on Targeted Antioxidant Therapy and Vitiligo.

Zhang J, Hu W, Wang P, Ding Y, Wang H, Kang X Oxid Med Cell Longev. 2022; 2022:1821780.

PMID: 35320978 PMC: 8938057. DOI: 10.1155/2022/1821780.

References

Zhao Y, Gartner U, Smith F, McLean W . Statins downregulate K6a promoter activity: a possible therapeutic avenue for pachyonychia congenita. J Invest Dermatol. 2011; 131(5):1045-52. DOI: 10.1038/jid.2011.41. View

Agarwal P, Rashighi M, Essien K, Richmond J, Randall L, Pazoki-Toroudi H . Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo. J Invest Dermatol. 2014; 135(4):1080-1088. PMC: 4366328. DOI: 10.1038/jid.2014.529. View

Komen L, da Graca V, Wolkerstorfer A, de Rie M, Terwee C, van der Veen J . Vitiligo Area Scoring Index and Vitiligo European Task Force assessment: reliable and responsive instruments to measure the degree of depigmentation in vitiligo. Br J Dermatol. 2014; 172(2):437-43. DOI: 10.1111/bjd.13432. View

Noel M, Gagne C, Bergeron J, Jobin J, Poirier P . Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo. Lipids Health Dis. 2004; 3:7. PMC: 425594. DOI: 10.1186/1476-511X-3-7. View

Rashighi M, Agarwal P, Richmond J, Harris T, Dresser K, Su M . CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med. 2014; 6(223):223ra23. PMC: 4086941. DOI: 10.1126/scitranslmed.3007811. View